Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study

Area of Science:

• Nephrology
• Molecular Biology
• Biomarker Discovery

Background:

• MicroRNAs (miRNAs) are crucial noncoding RNA molecules implicated in kidney disease pathogenesis.
• Investigating circulating and urinary miRNA expression profiles in minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) could identify noninvasive biomarkers.

Purpose of the Study:

• To determine if distinct circulating and urinary miRNA expression profiles differentiate patients with MCD and FSGS.
• To explore the potential of these miRNA profiles as noninvasive diagnostic biomarkers for these kidney diseases.

Main Methods:

• Exosome miRNAs were extracted from plasma and urine of patients with primary FSGS (n=16), MCD (n=5), and healthy controls (n=5).
• MicroRNA abundance differences were analyzed using Affymetrix GeneChip miRNA 3.0 arrays and validated with quantitative reverse transcription PCR (QRT-PCR).

Main Results:

• Analysis revealed 126 and 155 differentially expressed miRNAs in plasma and urine between FSGS and MCD patients, respectively.
• Significant downregulation of miRNAs was observed in both plasma and urine of FSGS patients compared to MCD patients.
• Specific miRNAs (e.g., miR-30b, miR-30c, miR-34b, miR-34c, miR-342 in plasma; mir-1225-5p in urine) were upregulated in MCD, while others (mir-1915, miR-663 in urine) were downregulated in FSGS. Urinary miR-155 was upregulated in FSGS.

Conclusions:

• Patients with FSGS and MCD exhibit unique circulating and urinary miRNA expression profiles.
• The identified miRNA profiles hold potential for the development of diagnostic and prognostic noninvasive biomarkers for FSGS and MCD, warranting further investigation.